Re:암세포가 만들어내는 젖산(acidosis)을 어떻게 치료할 것인가?

[문형철]

beyond reason

암세포는 포도당만을 에너지로 사용하고 해당과정(glycolysis)을 통해 무산소적으로 2개의 ATP를 만드는과정에서 젖산을 분비함. 젖산에 의한 산성환경은 정상 면역세포의 항암반응을 무력화시킴. 

Glutaminolysis 

암세포의 특성중 하나임. 글루타민분해는 임파구,  thymocyte, colonocyte, 지방세포, 암세포에서 세포증식의 역할을 담당함. 글루타민은 포도당과 함께 암세포의 에너지 생성기둥임. high extracellular 글루타민 농도는 암세포 성장을 자극함. 반면에 글루타민 농도가 낮으면 phenotypical and functional differentiation of the cells 관련됨. 

Glutaminolysis: an important energy source in tumor cells[edit]

Glutaminolysis takes place in all proliferating cells,^[21] such as lymphocytes, thymocytes, colonocytes, adipocytes and especially in tumor cells.^{[1][2][3][4][5][6][7][8][10][11][12][13][14][16][18][19][22]} In tumor cells the citric acid cycle is truncated due to an inhibition of the enzyme aconitase (EC 4.2.1.3) by high concentrations of reactive oxygen species (ROS)^[23][24] Aconitase catalyzes the conversion of citrate to isocitrate. On the other hand, tumor cells over express phosphate dependent glutaminase and NAD(P)-dependent malate decarboxylase,^{[9][25][26][27][28]} which in combination with the remaining reaction steps of the citric acid cycle from α-ketoglutarate to citrate impart the possibility of a new energy producing pathway, the degradation of the amino acid glutamine to glutamate, aspartate, pyruvate CO₂, lactate and citrate.

Besides glycolysis in tumor cells glutaminolysis is another main pillar for energy production. High extracellular glutamine concentrations stimulate tumor growth and are essential for cell transformation.^[27][29] On the other hand, a reduction of glutamine correlates with phenotypical and functional differentiation of the cells.^[30]

Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite?

Stephen Yiu Chuen Choi, Colin C Collins, [...], and Yuzhuo Wang

Additional article information

Abstract

The common preference of cancers for lactic acid-generating metabolic energy pathways has led to proposals that their reprogrammed metabolism confers growth advantages such as decreased susceptibility to hypoxic stress. Recent observations, however, suggest that it generates a novel way for cancer survival. There is increasing evidence that cancers can escape immune destruction by suppressing the anti-cancer immune response through maintaining a relatively low pH in their micro-environment. Tumours achieve this by regulating lactic acid secretion via modification of glucose/glutamine metabolisms. We propose that the maintenance by cancers of a relatively low pH in their micro-environment, via regulation of their lactic acid secretion through selective modification of their energy metabolism, is another major mechanism by which cancers can suppress the anti-cancer immune response. Cancer-generated lactic acid could thus be viewed as a critical, immunosuppressive metabolite in the tumour micro-environment rather than a ‘waste product’. This paradigm shift can have major impact on therapeutic strategy development. 

Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Keywords: Warburg effect, aerobic glycolysis, glutaminolysis, lactic acid, immune suppression, tumour micro-environment

Introduction

Deregulated proliferation of cancer cells is generally associated with altered energy metabolism. Glucose is a primary source of energy. Under aerobic conditions, normal cells metabolize glucose to pyruvate via glycolysis in the cytosol, and subsequently convert pyruvate to carbon dioxide in the mitochondria for oxidative phosphorylation; under anaerobic conditions, conversion of pyruvate to lactic acid is favoured with relatively low amounts of pyruvate being diverted to the mitochondria. In contrast, cancer cells primarily derive energy from glucose via glycolysis to lactic acid, even under highly aerobic conditions, a property first observed by Otto Warburg 1. This ‘aerobic glycolysis’, also known as the ‘Warburg effect’ 2, is much less energy-efficient than the oxidative phosphorylation pathway 3. It is usually accompanied by marked increases in glucose uptake and consumption 4, a phenomenon commonly exploited in tumour imaging using 18-fluorodeoxyglucose positron electron tomography 5. In addition, cancer cells derive energy from up-regulated non-glucose-dependent pathways, such as increased glutaminolysis under aerobic conditions 2,6,7. Aerobic glycolysis and increased glutaminolysis are collectively regarded as ‘reprogrammed energy metabolism’, a phenomenon now generally accepted as a key metabolic hallmark of cancer 3,8,9. Both pathways lead to the production and secretion of lactic acid, markedly contributing to metabolic acidosis commonly found in solid cancers 2,6,7. Extracellular pH values in tumours can be as low as pH 6.0–6.5, in contrast to pH 7.5 present in normal cell environments 10–12.

Why do cancers opt for altered energy metabolism?

The preference of cancers for aerobic glycolysis over the more energy-efficient oxidative phosphorylation pathway has been a subject of major interest since it was first observed in the 1920s 13. Many researchers have speculated on the advantages of aerobic glycolysis for cancers, but the causal relationship of this altered metabolism to cancer development is still unclear 3. Otto Warburg speculated that the metabolic alteration was necessitated by a mitochondrial defect in the cancer cells impairing normal oxidative phosphorylation 14. However, further studies have since shown that mitochondrial defects only partially account for the phenomenon. Although certain malignancies indeed harbour mitochondrial defects that make aerobic glycolysis a necessity 15, the majority of cancers are able to revert back to oxidative phosphorylation when lactic acid generation is inhibited 16.

Tumours commonly encounter fluctuating oxygen levels, periodically alternating between normoxic and hypoxic conditions 17. This raises the distinct possibility that aerobic glycolysis has arisen as an adaptation to hypoxic conditions. Use of oxygen-independent glycolysis would confer a proliferative advantage to cancer cells, making them less susceptible to hypoxic stress during episodes of spontaneous hypoxia 13, even if that would come at a cost of energy inefficiency during times of adequate oxygenation. This theory has been extended by suggesting cooperation between normoxic and hypoxic cancer cells within a tumour aimed at maximizing energy efficiency 2. It is proposed that the hypoxic cells are the primary utilizers of glucose, converting it via glycolysis to lactate. Furthermore, lactate secreted by the hypoxic cells would be taken up by normoxic cancer cells and then converted back to pyruvate for oxidation via the citric acid cycle 2,18. This theory, however, does not fully account for the preference of cancers for glycolysis under conditions of abundant oxygenation.

Components of glucose uptake and glycolytic pathways can be up-regulated by oncogenes such as Ras, Akt, and Myc 3. This observation is particularly intriguing, since oncogenic activation is often thought of as an early event in cancer development and progression, and aerobic glycolysis may hence actually predate the onset of hypoxic selection and have a functional role in the early stages of the disease. Other proposals have been put forward, primarily focusing on the mechanisms by which aerobic glycolysis could confer a proliferative advantage to cancer cells 3,13,19. As this pathway is much less efficient than oxidative phosphorylation in generating ATP, ie by approximately 18-fold, the question is raised as to how a reduced supply of ATP can lead to improved proliferative potential. One proposal states that the advantage of aerobic glycolysis lies in incomplete utilization of glucose, allowing upstream intermediates to be redirected for biosynthesis, thereby providing cancer cells with an abundance of building blocks for synthesis of essential cellular components such as macromolecules 19. While such an explanation appears sound, there is still controversy regarding how common such a mechanism is in normal proliferating cells 20. Another proposal states that acidification of the micro-environment by lactic acid, resulting from up-regulation of glycolysis, can be expected to lead to the development of acid-resistant phenotypes exhibiting a powerful, selective growth advantage that promotes unconstrained proliferation and tissue invasion of cancer cells 13.

Increased glutaminolysis would also have several advantages for cancers: glutamine is the most abundant amino acid in plasma and forms an important additional energy source in tumour cells, especially when glycolytic energy production is low; increased availability of the degradation products of glutamine, ie glutamate and aspartate, as precursors for nucleic acid and serine synthesis; and the insensitivity of glutaminolysis to high concentrations of reactive oxygen species 2,6,7.

Of major interest is the finding that the reprogrammed energy metabolism plays an important role in cancer growth-promoting angiogenesis. Angiogenic endothelial cells, like tumour cells, are largely dependent on aerobic glycolysis and increased glutaminolysis for energy. The preference for these pathways allows the development of neovasculature from endothelial, tumour-blood-vessel-lining cells under hypoxic conditions. In addition, lactic acid generated by the pathways has been found to markedly promote angiogenesis by increasing the production of interleukin-8/CXCL8, driving the autocrine stimulation of endothelial cell proliferation and maturation of new blood vessels 21,22.

Altered energy metabolism and evasion of immune destruction—lactic acid as a critical, regulatory metabolite

Recent studies indicate that altered energy metabolism can also enhance the growth of cancers by promoting tumour evasion of immune destruction. It is now commonly accepted that a transformed, immunogenic cell can only develop into a tumour if it has the ability to evade the cytotoxic immune response that it evokes 8,23. The anti-cancer immune response, as it is mediated by effector T-cells, has long been known to be highly dependent on components of the micro-environment such as helper cells and cytokines. However, it is also influenced by the environmental pH; an acidic pH can markedly impede the function of normal immune cells 24,25. Lowering the environmental pH to 6.0–6.5, as can be found in tumour masses, has been reported to lead to loss of T-cell function of human and murine tumour-infiltrating lymphocytes (eg impairment of cytolytic activity and cytokine secretion); the T-cell function could be completely restored by buffering the pH at physiological values 11.

The primary cause responsible for the acidic pH and pH-dependent T-cell function-suppressive effect in a tumour micro-environment has been identified as lactic acid 26–30. It has also been demonstrated that cancer-generated lactic acid and the resultant acidification of the micro-environment increase the expression‎ of ARG1 in tumour-associated macrophages, characteristic of the M2 helper phenotype 31. Furthermore, another study showed that under physiological or slightly alkaline conditions, glycolysis was selectively up-regulated by neuroblastoma cells, whereas oxidative phosphorylation was preferred by the cells when the extracellular pH was acidic; these effects were independent of changes in oxygen concentration or glucose supply 32. Thus, aerobic glycolysis can serve as a negative feedback loop that adjusts the pericellular pH in tumours towards a broad acidic range by increased lactic acid production and secretion. Taken together, the studies suggest that cancer cells can enhance their survival by inhibiting the anti-cancer immune response through actively maintaining a slightly acidic micro-environment. They apparently can do this by altering their energy metabolism to regulate their lactic acid production/secretion 32. The locally suppressed immunity then serves as a basis for the establishment of the malignancy and its subsequent malignant progression (see Figure 1).

Figure 1

A proposed model for the central, regulatory immunosuppressive role of cancer-generated lactic acid with both experimentally demonstrated (in black) and potential (in grey) consequences. The excess lactic acid produced by cancer cells through reprogrammed ...

In view of the above, researchers are starting to attribute a critical, regulatory role to lactic acid rather than regarding it as a mere metabolic waste product 13,33. Supporting this hypothesis are reports that lactic acid has been found to be a key player in the development and malignant progression of a variety of cancers, with high tumour lactate levels being predictive of metastasis and restricted patient survival 33,34. In addition, lactate dehydrogenase A, the enzyme that catalyses the conversion of pyruvate to lactate, has been found to play an important role in the malignant progression of oesophageal squamous cell carcinoma 35 and tumourigenicity of intestinal-type gastric cancer 36. Furthermore, evidence has been found for involvement of the plasma membrane lactate transporter, MCT4, in breast 37 and prostate 38 cancer.

Immunosuppressive effect of cancers and epithelial immune cell-like transition (EIT)

As previously reviewed, there apparently are various ways by which epithelial cancers can suppress an anti-cancer immune response 39. We have proposed that their immunosuppressive ability may stem from an acquisition of specific immune cell properties via a transdifferentiation process that we coined ‘epithelial immune cell-like transition’ (EIT) 39. The acquired properties enable cancer cells to suppress the anti-cancer activity of immune cells in their micro-environment by, for example, secreting chemokines to enhance recruitment of T-regulatory cells to the tumour site or producing immunosuppressive cytokines. In this context, the suppression of the immune response by cancers through controlled, lactic acid-induced acidification of their micro-environment appears to be yet another mechanism by which cancers can locally suppress the immune system in an otherwise immunocompetent host.

Implications for cancer therapy

Aerobic glycolysis and increased glutaminolysis are preferred metabolic energy-generating pathways of cancer 2,8,9 and also have, as mentioned above, an important role in tumour angiogenesis due to the angiogenesis-stimulating effect of lactic acid and the dependence of endothelial cells on this altered metabolism for energy under hypoxic as well as normoxic conditions 21,22. Furthermore, as described above, a growing body of evidence indicates that this altered energy metabolism leads to lactic acid-induced acidification of the cancer micro-environment suppressing the anti-cancer immune response 11,26–30. Targeting these altered metabolic pathways could therefore lead to inhibition of cancer growth based on energy deprivation, in particular under hypoxic conditions, and the growth-inhibitory effects would be especially marked if accompanied by inhibition of tumour angiogenesis and by restoration of the anti-cancer immune response in the micro-environment of the cancers. Additionally, the production of reactive oxygen species (ROS) in the mitochondria is closely tied to normal oxidative metabolism. While the generation of ROS is often associated with tumour progression through damage to DNA and other cellular components, it is suggested that these species play a critical role in regulating various normal physiological processes such as immune function and autophagy 40. As such, the inhibition of lactic acid production in cancer cells may help to re-establish physiological ROS homeostasis and restore normal cellular functions. One drawback of attempting to annihilate cancer through an energy deprivation approach, however, is the likelihood that normal cellular metabolism will also be disrupted; careful pharmacological considerations are therefore required 41. Furthermore, partial inhibition of angiogenesis may lead to normalization of tumour vasculatures, resulting in enhancement of tumour responses to chemotherapy, radiotherapy, and immunotherapy. A window of tumour vascular renormalization would need to be established to maximize the effects of targeting the altered metabolic pathways in combination with other strategies 42,43.

The restoration of the anti-cancer immune response may be accomplished not only through targeting of the two pathways leading to inhibition of lactic acid production 28, but also by interfering with pH regulators such as the proton pump, the sodium–proton exchanger family, and the bicarbonate transporter family 10–12,30,44,45; in this context, it is of interest that regulation of intracellular pH has recently been reported to involve histone acetylation 46. The latter strategies could be useful in combination with immunotherapeutic approaches. Thus far, however, strategies targeting aerobic glycolysis and increased glutaminolysis have often been mainly aimed at inhibiting invasive and metastatic behaviour of malignancies and have not focused on restoring or enhancing the immune response 10,45. Therapeutic effects are commonly examined in experimental immuno-deficient cancer models 47–49, instead of immuno-uncompromised models required to demonstrate effects on the immune response. Key components of the glycolytic pathway have been targeted and such endeavours have been extensively reviewed elsewhere 41,50, with a number of them showing promising results with regard to disease stabilization and tumour regression 49,51.

Altered glucose/glutamine metabolism is only one aspect of tumour metabolism. In addition to lactic acid, other metabolites that suppress T-cell function can be generated by tumours via alterations of lipid and adenosine metabolisms, eg indolamine-2,3-dioxygenase, arginase, inducible nitric oxide synthetase, and lactate dehydrogenase, important players in immune escape mechanisms. Pharmacological blockage of such metabolites could lead to improved cancer therapy by rescuing the endogenous immune response against tumour cells 52,53.

Conclusions

Lactic acid, commonly generated by cancers via reprogrammed energy metabolism (ie aerobic glycolysis, increased glutaminolysis), has a critical role in their growth as an immunosuppressive metabolite as well as a promoter of angiogenesis. Targeting altered, lactic acid-producing metabolisms of cancers may therefore lead to inhibition of their growth not only via energy/nutrition deprivation, but also through reduction of their immunosuppressive activity in the tumour micro-environment. This strategy, which simultaneously targets two fundamental cancer characteristics (ie altered energy metabolism and evasion of immune destruction), could be effective for the therapy of a broad range of cancers and could be particularly useful in combination with cancer immunotherapy.

Acknowledgments

We would like to thank Drs Hongwei Cheng, Fang Zhang, and Dong Lin of the BC Cancer Agency for helpful discussions. This study was supported in part by the Canadian Institutes of Health Research (YZW) and the BC Cancer Foundation. YZW was a recipient of an Overseas Chinese Scholar Award from the National Natural Science Foundation of China, and a recipient of an Innovative Scholar Award from The International Cancer Alliance for Research and Education (ICARE). He also received an award from the Tianjin Thousand Talents Program.

Author contribution statement

YZW initiated the topic in July 2012. SYCC and PWG organized the manuscript. SYCC, CC, PWG, and YZW were involved in the further development of the ideas and the writing of the paper.

Article information

J Pathol. 2013 Aug; 230(4): 350–355. 

Published online 2013 Jul 9. doi: 10.1002/path.4218

PMCID: PMC3757307

PMID: 23729358

Stephen Yiu Chuen Choi,1 Colin C Collins,2,3 Peter W Gout,1,* and  Yuzhuo Wang1,2,3,*

1Department of Experimental Therapeutics, BC Cancer Agency, Vancouver, British Columbia, Canada

2Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

3Vancouver Prostate Centre, Vancouver, British Columbia, Canada

*Correspondence to: YZ Wang, PhD or Peter W Gout, PhD, Department of Experimental Therapeutics, BC Cancer Agency—Cancer Research Centre, 675 West 10th Avenue, Vancouver, British Columbia, Canada V5Z 1L3. e-mail: ac.crccb@gnawy or ac.crccb@tuogp

No conflicts of interest were declared.

Received 2013 Apr 26; Revised 2013 May 26; Accepted 2013 May 28.

Copyright © 2013 Pathological Society of Great Britain and Ireland

Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.

This article has been cited by other articles in PMC.

References

1. Warburg O. On respiratory impairment in cancer cells. Science. 1956;124::269–270. [PubMed] [Google Scholar]

2. Feron O. Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother Oncol. 2009;92::329–333.[PubMed] [Google Scholar]

3. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell. 2008;134::703–707. [PubMed] [Google Scholar]

4. Shaw RJ. Glucose metabolism and cancer. Curr Opin Cell Biol. 2006;18::598–608. [PubMed] [Google Scholar]

5. Jadvar H, Alavi A, Gambhir SS. 18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med. 2009;50::1820–1827. [PMC free article] [PubMed] [Google Scholar]

6. DeBerardinis RJ, Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene. 2010;29::313–324.[PMC free article] [PubMed] [Google Scholar]

7. Deberardinis RJ, Sayed N, Ditsworth D, et al. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev. 2008;18::54–61. [PMC free article][PubMed] [Google Scholar]

8. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144::646–674. [PubMed] [Google Scholar]

9. Daye D, Wellen KE. Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis. Semin Cell Dev Biol. 2012;23::362–369.[PubMed] [Google Scholar]

10. Webb BA, Chimenti M, Jacobson MP, et al. Dysregulated pH: a perfect storm for cancer progression. Nature Rev Cancer. 2011;11::671–677. [PubMed] [Google Scholar]

11. Calcinotto A, Filipazzi P, Grioni M, et al. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res. 2012;72::2746–2756. [PubMed] [Google Scholar]

12. De Milito A, Canese R, Marino ML, et al. pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer. 2010;127::207–219. [PubMed] [Google Scholar]

13. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nature Rev Cancer. 2004;4::891–899. [PubMed] [Google Scholar]

14. Warburg O. On the origin of cancer cells. Science. 1956;123::309–314.[PubMed] [Google Scholar]

15. Chandra D, Singh KK. Genetic insights into OXPHOS defect and its role in cancer. Biochim Biophys Acta. 2011;1807:620–625. [PMC free article] [PubMed] [Google Scholar]

16. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression‎ uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. 2006;9::425–434. [PubMed] [Google Scholar]

17. Kimura H, Braun RD, Ong ET, et al. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res. 1996;56::5522–5528. [PubMed] [Google Scholar]

18. Draoui N, Feron O. Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments. Dis Model Mech. 2011;4::727–732. [PMC free article][PubMed] [Google Scholar]

19. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324::1029–1033. [PMC free article] [PubMed] [Google Scholar]

20. Zu XL, Guppy M. Cancer metabolism: facts, fantasy, and fiction. Biochem Biophys Res Commun. 2004;313::459–465. [PubMed] [Google Scholar]

21. Harjes U, Bensaad K, Harris AL. Endothelial cell metabolism and implications for cancer therapy. Br J Cancer. 2012;107::1207–1212.[PMC free article] [PubMed] [Google Scholar]

22. Polet F, Feron O. Endothelial cell metabolism and tumour angiogenesis: glucose and glutamine as essential fuels and lactate as the driving force. J Intern Med. 2013;273::156–165. [PubMed] [Google Scholar]

23. Hamaï A, Benlalam H, Meslin F, et al. Immune surveillance of human cancer: if the cytotoxic T-lymphocytes play the music, does the tumoral system call the tune? Tissue Antigens. 2010;75::1–8. [PubMed] [Google Scholar]

24. Lardner A. The effects of extracellular pH on immune function. J Leukoc Biol. 2001;69::522–530. [PubMed] [Google Scholar]

25. Kellum JA. Metabolic acidosis in patients with sepsis: epiphenomenon or part of the pathophysiology? Crit Care Resusc. 2004;6::197–203. [PubMed] [Google Scholar]

26. Kellum JA, Song M, Li J. Lactic and hydrochloric acids induce different patterns of inflammatory response in LPS-stimulated RAW 264.7 cells. Am J Physiol Regul Integr Comp Physiol. 2004;286::R686–R692. [PubMed] [Google Scholar]

27. Gottfried E, Kunz-Schughart LA, Ebner S, et al. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression‎. Blood. 2006;107::2013–2021. [PubMed] [Google Scholar]

28. Fischer K, Hoffmann P, Voelkl S, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007;109::3812–3819. [PubMed] [Google Scholar]

29. Goetze K, Walenta S, Ksiazkiewicz M, et al. Lactate enhances motility of tumor cells and inhibits monocyte migration and cytokine release. Int J Oncol. 2011;39::453–463. [PubMed] [Google Scholar]

30. Mendler AN, Hu B, Prinz PU, et al. Tumor lactic acidosis suppresses CTL function by inhibition of p38 and JNK/c-Jun activation. Int J Cancer. 2012;131::633–640. [PubMed] [Google Scholar]

31. Ohashi T, Akazawa T, Aoki M, et al. Dichloroacetate improves immune dysfunction caused by tumor-secreted lactic acid and increases antitumor immunoreactivity. Int J Cancer. 2013; DOI:  10.1002/ijc.28114. [PubMed] [Google Scholar]

32. Mazzio EA, Boukli N, Rivera N, et al. Pericellular pH homeostasis is a primary function of the Warburg effect: inversion of metabolic systems to control lactate steady state in tumor cells. Cancer Sci. 2012;103::422–432.[PMC free article] [PubMed] [Google Scholar]

33. Sola-Penna M. Metabolic regulation by lactate. IUBMB Life. 2008;60::605–608. [PubMed] [Google Scholar]

34. Hirschhaeuser F, Sattler UG, Mueller-Klieser W. Lactate: a metabolic key player in cancer. Cancer Res. 2011;71::6921–6925. [PubMed] [Google Scholar]

35. Yao F, Zhao T, Zhong C, et al. LDHA is necessary for the tumorigenicity of esophageal squamous cell carcinoma. Tumour Biol. 2013;34::25–31. [PubMed] [Google Scholar]

36. Zhang Y, Zhang X, Wang X, et al. Inhibition of LDH-A by lentivirus-mediated small interfering RNA suppresses intestinal-type gastric cancer tumorigenicity through the downregulation of Oct4. Cancer Lett. 2012;321::45–54. [PubMed] [Google Scholar]

37. Gallagher SM, Castorino JJ, Wang D, et al. Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. Cancer Res. 2007;67::4182–4189. [PubMed] [Google Scholar]

38. Pértega-Gomes N, Vizcaíno JR, Miranda-Gonçalves V, et al. Monocarboxylate transporter 4 (MCT4) and CD147 overexpression‎ is associated with poor prognosis in prostate cancer. BMC Cancer. 2011;11::312.[PMC free article] [PubMed] [Google Scholar]

39. Choi SY, Gout PW, Collins CC, et al. Epithelial immune cell-like transition (EIT): a proposed transdifferentiation process underlying immune-suppressive activity of epithelial cancers. Differentiation. 2012;83::293–298. [PubMed] [Google Scholar]

40. Sena LA, Chandel NS. Physiological roles of mitochondrial reactive oxygen species. Mol Cell. 2012;48::158–167. [PMC free article] [PubMed] [Google Scholar]

41. Scatena R, Bottoni P, Pontoglio A, et al. Glycolytic enzyme inhibitors in cancer treatment. Expert Opin Investig Drugs. 2008;17::1533–1545. [PubMed] [Google Scholar]

42. Matsumoto S, Batra S, Saito K, et al. Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia. Cancer Res. 2011;71::6350–6359. [PMC free article] [PubMed] [Google Scholar]

43. Goel S, Duda DG, Xu L, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011;91::1071–1121.[PMC free article] [PubMed] [Google Scholar]

44. Izumi H, Torigoe T, Ishiguchi H, et al. Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. Cancer Treat Rev. 2003;29::541–549. [PubMed] [Google Scholar]

45. Robey IF, Baggett BK, Kirkpatrick ND, et al. Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res. 2009;69::2260–2268.[PMC free article] [PubMed] [Google Scholar]

46. McBrian MA, Behbahan IS, Ferrari R, et al. Histone acetylation regulates intracellular pH. Mol Cell. 2013;49::310–321. [PMC free article] [PubMed] [Google Scholar]

47. Buijs M, Vossen JA, Geschwind JF, et al. Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer. Invest New Drugs. 2009;27::120–123. [PubMed] [Google Scholar]

48. Kim HS, Masko EM, Poulton SL, et al. Carbohydrate restriction and lactate transporter inhibition in a mouse xenograft model of human prostate cancer. BJU Int. 2012;110::1062–1069. [PMC free article] [PubMed] [Google Scholar]

49. Anastasiou D, Yu Y, Israelsen WJ, et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nature Chem Biol. 2012;8::839–847. [PMC free article] [PubMed] [Google Scholar]

50. Pelicano H, Martin DS, Xu RH, et al. Glycolysis inhibition for anticancer treatment. Oncogene. 2006;25::4633–4646. [PubMed] [Google Scholar]

51. Guais A, Baronzio G, Sanders E, et al. Adding a combination of hydroxycitrate and lipoic acid (METABLOC™) to chemotherapy improves effectiveness against tumor development: experimental results and case report. Invest New Drugs. 2012;30::200–211. [PubMed] [Google Scholar]

52. Singer K, Gottfried E, Kreutz M, et al. Suppression of T-cell responses by tumor metabolites. Cancer Immunol Immunother. 2011;60::425–431. [PubMed] [Google Scholar]

53. Villalba M, Rathore MG, Lopez-Royuela N, et al. From tumor cell metabolism to tumor immune escape. Int J Biochem Cell Biol. 2013;45::106–113.[PubMed] [Google Scholar]